Denali Therapeutics Inc (DNLI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.00B
Last updated: Nov 17, 2026 at 11:04 AM ET
Denali Therapeutics Inc (DNLI) Financials: Revenue, Profit and Cash Flow
Denali Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$512.54M, operating cash flow was -$412.60M and free cash flow was -$422.10M. The quarter ended Sep 30, 2026 had revenue of $17.78M and net income of $70.13M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $555.34M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2023 | $330.53M | +204.7% | 100.0% | -59.5% | -43.9% |
| Dec 2022 | $108.46M | +122.9% | 100.0% | -314.2% | -300.6% |
| Dec 2021 | $48.66M | -85.5% | 100.0% | -607.8% | -597.2% |
| Dec 2020 | $335.66M | +1158.2% | 100.0% | 18.7% | 21.2% |
| Dec 2019 | $26.68M | -79.3% | 100.0% | -799.1% | -740.7% |
| Dec 2018 | $129.16M | N/A | 100.0% | -35.9% | -28.1% |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.53M | $108.46M | $48.66M | $335.66M | $26.68M | $129.16M | $0 | $0 |
| Gross profit | $0 | $0 | $330.53M | $108.46M | $48.66M | $335.66M | $26.68M | $129.16M | $0 | $0 |
| Research and development | $418.78M | $396.44M | $423.88M | $358.73M | $265.35M | $212.62M | $193.38M | $143.18M | $74.46M | $75.70M |
| Operating income | -$555.34M | -$487.34M | -$196.70M | -$340.74M | -$295.75M | $62.72M | -$213.18M | -$46.37M | -$90.14M | -$87.43M |
| Net income | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -$290.58M | $71.14M | -$197.61M | -$36.24M | -$88.19M | -$86.65M |
| EBITDA | -$540.53M | -$478.35M | -$179.97M | -$330.36M | -$278.41M | $71.30M | -$210.21M | -$41.66M | -$84.35M | -$85.66M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.78M | $3.60M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$305.04M |
| Gross profit | $17.59M | $3.51M | $0 | -$2.87M | $0 | $0 | $0 | N/A | $0 | $0 | $0 | -$307.22M |
| Operating income | -$126.75M | -$130.54M | -$137.36M | -$137.37M | -$137.43M | -$134.96M | -$145.58M | -$129.85M | -$123.19M | -$116.59M | -$117.72M | -$132.57M |
| Net income | $70.13M | -$127.55M | -$128.45M | -$128.55M | -$126.90M | -$124.12M | -$132.97M | -$114.75M | -$107.19M | -$99.03M | -$101.80M | -$119.47M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $9.55M by $195.78M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.14B | $1.37B | $1.15B | $1.46B | $1.40B | $1.60B | $553.23M | $661.98M | $486.72M | $271.07M |
| Current assets | $900.66M | $864.44M | $1.06B | $1.37B | $897.23M | $1.50B | $430.03M | $480.84M | $409.61M | $181.96M |
| Cash and equivalents | $205.33M | $174.96M | $127.11M | $218.04M | $293.48M | $507.14M | $79.45M | $77.12M | $218.38M | $39.85M |
| Total liabilities | $131.09M | $144.50M | $122.96M | $417.81M | $441.87M | $453.75M | $158.34M | $115.14M | $20.93M | $16.55M |
| Short-term debt | $9.55M | $12.03M | $7.26M | $7.32M | $5.45M | $4.69M | $3.67M | $19.09M | N/A | N/A |
| Shareholder equity | $1.01B | $1.23B | $1.03B | $1.04B | $962.29M | $1.15B | $394.89M | $546.85M | $465.80M | $254.52M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.26B | $1.16B | $1.27B | $1.14B | $1.06B | $1.17B | $1.27B | $1.37B | $1.45B | $1.50B | $1.58B | $1.15B |
| Total liabilities | $329.65M | $322.78M | $339.93M | $131.09M | $129.42M | $139.19M | $148.66M | $144.50M | $135.52M | $115.51M | $125.62M | $122.96M |
| Cash and equivalents | $102.87M | $201.53M | $387.63M | $205.33M | $90.96M | $141.21M | $56.95M | $174.96M | $90.64M | $74.68M | $60.57M | $127.11M |
| Shareholder equity | $926.39M | $835.18M | $926.10M | $1.01B | $926.20M | $1.03B | $1.12B | $1.23B | $1.32B | $1.39B | $1.46B | $1.03B |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$412.60M | -$347.69M | -$357.99M | -$244.72M | -$211.39M | $416.15M | -$151.58M | $50.12M | -$76.64M | -$71.91M |
| Capital expenditures | $9.50M | $15.91M | $12.94M | $17.83M | $8.50M | $3.10M | $17.92M | $3.39M | $2.88M | $6.13M |
| Free cash flow | -$422.10M | -$363.61M | -$370.93M | -$262.55M | -$219.89M | $413.06M | -$169.50M | $46.72M | -$79.51M | -$78.04M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.39M | $0 | $0 |
| Investing cash flow | $255.28M | -$88.76M | $249.31M | -$141.39M | -$21.63M | -$623.21M | $147.71M | -$287.42M | -$41.17M | -$219.00M |
| Financing cash flow | $189.22M | $484.30M | $17.82M | $310.67M | $19.35M | $634.75M | $6.19M | $97.02M | $296.32M | $300.48M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$117.44M | -$97.00M | -$131.20M | -$98.54M | -$107.30M | -$75.30M | -$131.47M | -$83.72M | -$59.14M | -$91.22M | -$113.62M | -$98.66M |
| Capital expenditures | $1.01M | $805.00K | $2.47M | $1.52M | $1.38M | $4.28M | $5.08M | $5.09M | $3.88M | $4.79M | $2.15M | $2.23M |
| Free cash flow | -$118.45M | -$97.81M | -$133.67M | -$100.06M | -$108.67M | -$79.58M | -$136.55M | -$88.81M | -$63.02M | -$96.01M | -$115.77M | -$100.89M |
Frequently Asked Questions About DNLI
What is Denali Therapeutics' annual revenue?
Denali Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Denali Therapeutics profitable?
No. Denali Therapeutics reported net income of -$512.54M for the fiscal year ended Dec 31, 2025.
How much free cash flow does DNLI generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$412.60M minus capital expenditures of $9.50M produced free cash flow of -$422.10M.
How much debt does Denali Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $9.55M and cash and equivalents of $205.33M.
DNLI pages: Overview, Earnings, Forecast, Financials, Competitors